Bone Marrow Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

April 2022 | 555 pages | ID: BE8D7EF78B28EN
Global Markets Direct

Abstracts

Bone Marrow Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Marrow Transplant Rejection - Drugs In Development, 2022, provides an overview of the Bone Marrow Transplant Rejection (Immunology) pipeline landscape.

Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body. Symptoms include chest pain, chills, drop in blood pressure, fever, flushing, funny taste in the mouth, headache, hives, nausea, pain and shortness of breath. Treatment includes immunosuppressive drugs.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bone Marrow Transplant Rejection - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Marrow Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 2, 12, 33, 29, 4, 64, 13 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 2, 13 and 2 molecules, respectively.

Bone Marrow Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Marrow Transplant Rejection (Immunology).
• The pipeline guide reviews pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Bone Marrow Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Bone Marrow Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Bone Marrow Transplant Rejection (Immunology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Bone Marrow Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Bone Marrow Transplant Rejection - Overview
Bone Marrow Transplant Rejection - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Bone Marrow Transplant Rejection - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bone Marrow Transplant Rejection - Companies Involved in Therapeutics Development
Bone Marrow Transplant Rejection - Drug Profiles
Bone Marrow Transplant Rejection - Dormant Projects
Bone Marrow Transplant Rejection - Discontinued Products
Bone Marrow Transplant Rejection - Product Development Milestones
Featured News & Press Releases
Apr 25, 2022: Equillium announces three poster presentations at the Transplantation & Cellular Meetings of the ASTCT and CIBMTR
Apr 25, 2022: Orca Bio presents positive data reinforcing clinical profile and manufacturing reliability of Orca-T at 2022 Transplantation & Cellular Therapy ASTCT and CIBMTR Tandem Meetings
Apr 21, 2022: INRAE and MaaT Pharma build on the success of their long-standing partnership with the entry of drug-candidate MaaT013 into phase 3 clinical trial
Apr 21, 2022: Rezurock (belumosudil) patient-reported outcomes correlated with clinical response in chronic graft-versus-host disease
Apr 04, 2022: Equillium announces oral presentation at the Italian Society of Experimental Hematology
Mar 28, 2022: MaaT Pharma announces first patient dosed in phase 3 ‘ARES’ trial evaluating MaaT013 in patients with acute Graft-vs-Host-Disease
Mar 25, 2022: Incyte announces positive CHMP opinion for ruxolitinib (Jakavi) for the treatment of acute and chronic graft-versus-host disease
Mar 23, 2022: Equillium announces two oral presentations at the Annual Meeting of the European Society for Blood and Marrow Transplantation
Mar 23, 2022: VectivBio presents preclinical data supporting Apraglutide for treatment of Acute Graft-Versus-Host Disease at the 48th annual meeting of the European Society for Blood and Marrow Transplantation
Mar 18, 2022: Seres Therapeutics presents preclinical research on investigational microbiome therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting
Mar 17, 2022: MaaT Pharma to present promising clinical data for lead therapeutic candidate MaaT013 at 48th EBMT Annual Meeting
Mar 07, 2022: Equillium begins Phase III acute graft-versus-host disease trial
Feb 28, 2022: AbbVie seeks new indication for IMBRUVICA (ibrutinib) in pediatric patients with chronic graft versus host disease (cGVHD)
Feb 17, 2022: Veloxis Pharmaceuticals' VEL-101 Granted FDA Fast Track Designation
Feb 01, 2022: FDA approves abatacept for prophylaxis of acute graft versus host disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Bone Marrow Transplant Rejection, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Bone Marrow Transplant Rejection - Dormant Projects, 2022
Bone Marrow Transplant Rejection - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Bone Marrow Transplant Rejection, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022